Exercise testing as an outcome of therapeutic interventions
Chairs: L. Puente-Maestu & P. Palange
Exercise intolerance is one, if not the most, of the deleterious consequences of pulmonary diseases that has a great impact on patients’ quality of life. Moreover, exercise tolerance is independently related to mayor outcomes such as survival, rate of hospital admissions and overall cost of pulmonary diseases such as COPD. Thus, because exercise tolerance is an important outcome and its assessment, while complex, will result in a better management of patients. Moreover, measuring exercise tolerance is becoming a very relevant issue for both medical practice and in clinical trials.
During the last years a great amount of evidence has been produced regarding the use of exercise testing as an outcome for interventions in lung diseases. However, most aspects regarding the cost, safety, feasibility, reliability, responsiveness, and comparative value of the different variables obtained during exercise (e.g., V’O2, V’E/V’CO2 slope, IC, HR recovery) to assess the effect of therapeutic interventions and the value of associated physiological measurements are quite disperse in the literature.
A very important objective of this Task Force is to discuss the “lights and shadows” of the different exercise protocols (e.i., endurance tests and 6MWT) commonly utilised for the evaluation of therapeutic interventions. Another important aim is to discuss the effects of therapeutic interventions on the level of day life physical activity.